Stereotaxis, Inc. 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 7, 2013, details material transactions regarding convertible debt and reports preliminary financial results for the second quarter of fiscal year 2013 ended June 30, 2013. Stereotaxis, Inc. is a medical technology company facing significant liquidity challenges and Nasdaq listing compliance issues.
Key Financial Metrics
| Metric | Q2 2013 | Q2 2012 | Q1 2013 |
|---|---|---|---|
| Revenue | $9.7 million | $10.5 million | $8.4 million |
| Gross Margin | 74.6% | 69.0% | 73.9% |
| Operating Loss | $(1.8) million | $(4.6) million | $(3.6) million |
| Net Loss | $(3.0) million | $2.8 million (Income) | $(4.9) million |
| Diluted EPS | $(0.37) | $0.32 | $(0.61) |
| Cash Burn | $2.2 million | $4.2 million | $1.1 million |
Liquidity and Capitalization (as of June 30, 2013):
- Cash and Equivalents: $4.1 million (Actual); projected to increase to $12.6 million following recent warrant exercises.
- Total Debt: $29.9 million, including $18.5 million in HealthCare Royalty Partners debt.
- Stockholders' Equity: $(25.6) million deficit.
Material Changes and Transactions
Convertible Debt Restructuring: On August 7, 2013, the company completed transactions with all holders of its convertible subordinated notes:
- Warrant Exercise: Holders exercised warrants for 2.5 million shares at $3.361/share, generating $8.475 million in cash proceeds.
- Note Conversion: $8.0 million principal amount of notes converted into 2.4 million shares.
- Exchange Agreement: Remaining $100,000 principal exchanged for 333,000 shares and new warrants for 2.5 million shares.
- Covenant Relief: The exchange removed restrictive covenants regarding use of proceeds and additional issuances, and holders released the company from prior defaults.
Operational Performance: System revenue increased 49% sequentially to $3.3 million, driven by Niobe ES system sales. However, overall utilization declined 11% year-over-year. Operating expenses decreased 24% year-over-year due to cost management.
Outlook, Risks, and Contingencies
Liquidity Risks: Despite the recent cash infusion, the company expects negative cash flow from operations throughout 2013. It has experienced significant liquidity issues, frequently breaching financial covenants on its senior secured credit facility, requiring monthly extensions and waivers from its lender (Silicon Valley Bank). The company is actively exploring strategic and financing alternatives, including a potential rights offering at $3.00 per share.
Nasdaq Listing Status: The company is not in compliance with Nasdaq Global Market listing standards regarding total assets, revenues, stockholders' equity, and market value of publicly held shares. It has requested a transfer to the Nasdaq Capital Market and is working to regain compliance by December 16, 2013. Delisting could trigger defaults on debt obligations and impair financing ability.
Clinical Updates: Received FDA 510(k) clearance for the Vdrive with V-Sono ICE catheter manipulator. The V-Loop circular catheter manipulator clinical study is 60% enrolled.
Investor Verification Checklist
- Verify the final terms and closing of the proposed rights offering to determine dilution impact.
- Monitor the outcome of the Nasdaq Listing Qualifications Panel hearing regarding the transfer to the Capital Market.
- Assess the sustainability of the revolving credit facility given the history of covenant waivers and extensions.
- Review the company's ability to raise additional capital if the rights offering is insufficient to cover operating cash burn.
- Confirm the status of the $18.5 million HealthCare Royalty Partners debt and any associated royalty obligations.